Second-Generation Antipsychotics as Adjunctive Therapy for Depression

Second-generation (also known as atypical) antipsychotics are increasingly used as adjunctive therapy for patients with major depressive disorder who have an inadequate or partial response to antidepressants. This course reviews the clinical rationale for their use, highlights newly approved options, and examines key safety, efficacy, and monitoring considerations. You will gain practical guidance to support patient selection, counseling, and shared decision-making when these agents are incorporated into depression management.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Sarah Grady, PharmD, BCPS, BCPP
Professor of Pharmacy Practice, Clinical Pharmacist
Drake University/Broadlawns Medical Center

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only.
To learn more about Health Mart, click here: https://join.healthmart.com/

PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Explain the role of second-generation (atypical) antipsychotics as adjunctive therapy in the management of major depressive disorder.
2. Identify pharmacist-relevant considerations for counseling, monitoring, and risk benefit assessment when second-generation antipsychotics are used for depression.

Rachel Maynard and Sarah Grady have no relevant financial relationships to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-059-H01-P
Initial release date: 3/16/2026
Expiration date: 3/16/2027

Additional CPE details can be found here.